UK Authorizes New Oral Medication for Type 2 Diabetes and Weight Loss

The UK's MHRA has approved Eli Lilly's Orforglipron (Foundayo), a new daily oral pill for type 2 diabetes and weight management, making it the first European country to do so. This offers an alternative for patients unable to use injectable weight-loss medications, potentially improving access to treatment. However, pharmacists warn of increasing counterfeit GLP-1 tablets.